Market Overview

Oppenheimer Initiates Tonix Pharmaceuticals With Outperform

Related CNS
Lazard (LAZ) Reflects Organic Growth: Time to Buy the Stock?
Earnings Scheduled For January 18, 2017

Oppenheimer initiated coverage on Tonix Pharmaceuticals (NYSE: TNXP) with an Outperform rating.

The target price is set to $18.

Editor's note: A previous version of this article incorrectly stated that Oppenheimer initiated coverage on Cohen & Steers, Inc. (NYSE: CNS) with a Outperform rating.

Latest Ratings for CNS

Jan 2018Keefe Bruyette & WoodsDowngradesMarket PerformUnderperform
Jan 2018Gabelli & Co.DowngradesBuyHold
Oct 2017Bank of AmericaMaintainsUnderperform

View More Analyst Ratings for CNS
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (CNS)

View Comments and Join the Discussion!